701P Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) Tx: Results from IMPACT UC

M.A Bilen,A.D Xi,A Wong,A Schroeder,R Kim,F.X Liu,J Peng,S Robinson,A Bhanegaonkar

doi:10.1016/j.annonc.2021.08.097

701P Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) Tx: Results from IMPACT UC

M.A Bilen, A.D Xi + Show 7 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.097

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
Citations: 3	License type: publisher-specific-oa

Affiliation: Emory University, Prevea Health, Pfizer (United States), Merck (Germany)

#Immuno-oncology Monotherapy #1L Setting + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Urothelial cancer (UC) is the most common malignancy involving the urinary system. The objective of IMPACT UC was to assess Tx patterns and clinical outcomes among Medicare Fee-for-Service (FFS) pts with mUC treated with chemotherapy or immuno-oncology monotherapy (IO-mono) in the 1L setting.

Full Text